November 27, 2020

The Niche

Knoepfler lab stem cell blog

Mesoblast

3 min read

The COVID-19 pandemic is tearing through the country right as we are starting into the holiday season, but the wheels of science including cell biology keep going and we keep reading all the great work. What news or papers caught your eye? Here are some of the things I have on my list of reading. Also, check out our most-read topic here on The Niche of the last month or so in two posts here and here digging into what I see as Duke’s cord …Read More

6 min read

Graft-versus-host disease (GVHD) is counterintuitive In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow transplant (BMT). Eighty Percent Mortality BMT has been used for more than half a century to treat and possibly cure certain cancers and single-gene conditions like sickle cell disease, …Read More

3 min read

Today’s post is the latest edition of my weekly recommended reads, which this week include Fate Therapeutics, COVID-19 updates, AAMC, and more including some great pubs such as one on 2 modes of PRC2 function. Also check out this handy resource: Helpful 2020 List of Stem Cell Journals and this blast from the past post of 10 years ago: Keep Your Stem Cells Away From BPA. I’ll start with the mid-August 2020 recommended pubs and then go to the media items, but first I wanted to …Read More

5 min read

The biotech Mesoblast is starting an expanded access study of its stem cell product for kids with a severe offshoot of COVID-19. The cellular drug in this case is remestemcel-L (more below). While most children fare better than adults in dealing with COVID-19, the rare subset of kids with COVID-19 for this study have more severe disease than the average COVID patient and some die. Physicians need more potential treatment options here for these children. In that sense one could argue that testing more new …Read More